German CDISC UG Meeting
Ingelheim, 05. September 2017

Introduction to Boehringer Ingelheim
Introduction

Andrea Rauch
Global Head of Clinical Data Standards
Boehringer Ingelheim in brief

- Family-owned global corporation
- Founded 1885 in Ingelheim, Germany
- Focus on Human pharmaceuticals, Animal health and biopharmaceutical contract manufacturing
- Around 45,700 employees worldwide
- Four R&D sites worldwide
- R&D expenditure of EUR 3.1 billion
- 17 production facilities (human pharmaceuticals) in 11 countries
- Net sales of around EUR 15.9 billion
- 143 affiliated companies worldwide
- Investment in tangible assets: EUR 645 million

Global Research and Development presence in Europe, North America and Asia

- Industry-leading expertise in research, development and medicine
- Extensive capabilities in both small molecule drugs and biotherapeutics
- Actively extending our global community of innovation partners
- Research Beyond Borders capturing emerging science for and beyond our core therapeutic areas
Research and Development Innovation: Four focus areas

- Cardiometabolic diseases
- Central nervous system diseases
- Immunology and respiratory diseases
- Oncology research and cancer immunology